Clinical Trial Update: NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating NKG2D.Zeta-NK cell conditioning combined with C7R.GD2.CAR-T cells in patients with relapsed or refractory neuroblastoma or osteosarcoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Osteosarcoma

Drugs mentioned

• C7R-GD2.CAR T Cells
• NKG2D.Zeta-NK cell conditioning

Snippet

Sponsor: Baylor College of Medicine | Conditions: Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 | Status: NOT_YET_RECRUITING